Author

Wieke M. van Oostveen

Observed names: W. van Oostveen, Wieke M van Oostveen, Wieke van Oostveen

Institution: Leiden University Medical Center

Observed institutions: Leiden University, Cleveland Clinic, University of Louisville, Takasaki University of Health and Welfare, Leiden University Medical Center, Oncode Institute, Boehringer Ingelheim (United States)

ORCID: 0000-0002-5619-4508

Observed ORCID: 0000-0002-5619-4508

OpenAlex ID: A5080517518

Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring

2021 · Wieke M. van Oostveen, Elizabeth C. M. de Lange · International Journal of Molecular Sciences · 292

Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

2023 · Otávio Cabral-Marques, Guido Moll, et al. · Autoimmunity Reviews · 48

Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors

2021 · Hubert J. Sijben, Wieke M. van Oostveen, et al. · Scientific Reports · 13

Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin‐1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis

2024 · Wieke M. van Oostveen, Eva M. Hoekstra, et al. · Arthritis & Rheumatology · 9

Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases

2024 · Wieke M. van Oostveen, Tom W. J. Huizinga, et al. · Immunological Reviews · 7

Label-free detection of prostaglandin transporter (SLCO2A1) function and inhibition: insights by wound healing and TRACT assays

2024 · Tamara A. M. Mocking, Wieke M. van Oostveen, et al. · Frontiers in Pharmacology · 4

Autoantibodies in systemic sclerosis display a proinflammatory Fc glycosylation signature independent of systemic inflammation

2026 · Wieke M. van Oostveen, Abdulellah M. Alzahrani, et al. · Journal of Autoimmunity

Disease activity and anti-topoisomerase I antibody positivity are associated with elevated serum B cell activating factor levels and a B cell subset-wide reduction of BAFF-receptor expression in SSc

2026 · Abdulellah M Alzahrani, Stefan F H Neys, et al. · Lara D. Veeken

Autoantibodies directed against the angiotensin II type 1 receptor and the endothelin-1 type A receptor in patients with systemic sclerosis

2025 · Katherine E van der Wouden, Saad Ahmed, et al. · RMD Open

2025 · Wieke M. van Oostveen, Eva M. Hoekstra, et al. · Arthritis & Rheumatology

Pos0614 Autoantibodies Directed Against the Angiotensin Ii Type 1 Receptor and the Endothelin-1 Type a Receptor in Patients With Systemic Sclerosis

2025 · K.E. van der Wouden, S. Ahmed, et al. · Annals of the Rheumatic Diseases

Works count: 11

Citation count: 373

H-index: 5

I10-index: 3